RxDoctor Payments Data

Virginia Valentine

Family Health · Albuquerque, NMNPI 1740338086

Payments from drug & device makers

$93,060in general payments, 2019–2025

Across 237 payments — averaging $392.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$56K
  • Lilly USA, LLC$20K
  • Novo Nordisk$4K
  • Xeris Pharmaceuticals, Inc.$2K
  • Alfasigma USA, Inc.$2K
  • Eli Lilly$2K
  • plus $7K from 13 others

What the payments were for

  • Consulting fees$40,36543%
  • Speaking & faculty fees$35,56638%
  • Travel & lodging$9,22110%
  • Food & beverage$7,8978%
  • Education$120%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few family health providers in New Mexicoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,665
Medicare patients
15
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide48$51,755
FarxigaDapagliflozin Propanediol34$31,269
Tresiba Flextouch U-100Insulin Degludec43$28,857
Tresiba Flextouch U-200Insulin Degludec15$19,092
MounjaroTirzepatide13$16,069
OzempicSemaglutide17$15,640
JardianceEmpagliflozin13$14,493
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,703
Novolog FlexpenInsulin Aspart15$4,484
Metformin Hcl69$782
Atorvastatin Calcium46$573
Rosuvastatin Calcium22$535
Glimepiride38$498
Levothyroxine Sodium16$399
Gabapentin20$360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$20,235$67,82361 claims
Novo NordiskOzempic$3,823$15,64017 claims
Boehringer IngelheimJardiance$1,320$14,49313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family health providers in New Mexicoon file to place this against a meaningful peer group, so we don't.

Other family health in Albuquerque

Where these figures come from

Is this you, or does something look wrong? →